©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Nov 15, 2024; 16(11): 4528-4531
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4528
Published online Nov 15, 2024. doi: 10.4251/wjgo.v16.i11.4528
Elevated ETV4 expression in cholangiocarcinoma is linked to poor prognosis and may guide targeted therapies
Uchenna E Okpete, Haewon Byeon, Department of Digital Anti-Aging Healthcare (BK21), Inje University, Gimhae 50834, South Korea
Author contributions: Okpete UE and Byeon H contributed to this paper; Byeon H designed the study; Okpete UE involved in data interpretation, developed methodology; Okpete UE and Byeon H assisted with writing the article.
Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.
Corresponding author: Haewon Byeon, DSc, PhD, Academic Editor, Associate Professor, Director, Department of Digital Anti-Aging Healthcare (BK21), Inje University, No. 197 Injero, Gimhae 50834, South Korea. bhwpuma@naver.com
Received: August 25, 2024
Revised: September 21, 2024
Accepted: October 8, 2024
Published online: November 15, 2024
Processing time: 60 Days and 21.1 Hours
Revised: September 21, 2024
Accepted: October 8, 2024
Published online: November 15, 2024
Processing time: 60 Days and 21.1 Hours
Core Tip
Core Tip: Cholangiocarcinoma is a highly aggressive cancer with limited treatment options. The recent study by Wang et al highlights the prognostic value of the PEA3 subfamily genes (ETV1, ETV4, and ETV5), especially ETV4, as key indicators of poor survival. Elevated ETV4 expression is linked to aggressive tumor behavior and worse outcomes. These findings offer potential for personalized treatment strategies, but further large-scale validation is required to integrate ETV4 as a prognostic biomarker and therapeutic target in clinical practice, particularly in high-incidence regions.